ArticleChina CDC weekly2022
Disease Burden of Pancreatic Cancer - China, 1990-2019.
Article in China CDC weekly, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Family caregivers' needs at 6 months after pancreatic cancer surgery: A latent profile analysis.International journal of nursing studies advances · 2025Article
- Comparative trends in pancreatic cancer burden and risk factors in the USA and China (1990-2021): insights from GBD analysis.BMC gastroenterology · 2025Article
- Article
- Comparative analysis of pancreatic cancer burden attributable to high BMI in adults aged 70 and older: analysis of the GBD data in the United States, Australia, and Germany (2012-2021).Frontiers in oncology · 2025Article
- Genome-Wide CRISPR Screen Identifies Genes Involved in Metastasis of Pancreatic Ductal Adenocarcinoma.Cancers · 2024Article
- Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma.Frontiers in molecular biosciences · 2022Article
- Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma.Frontiers in molecular biosciences · 2022Article
- Cancer Burden and Attributable Risk Factors of Cancers in China: Epidemiological Insights and Comparisons With India.Cancer control : journal of the Moffitt Cancer CenterArticle
- Immunopotentiation effects of apigenin on NK cell proliferation and killing pancreatic cancer cells.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Pancreatic cancer is one of the most malignant tumors of the digestive tract, and the etiology is not clear. Pancreatic cancer has a poor prognosis and high mortality. What is added by this report?: Compared with 1990, the burden of pancreatic cancer in China increased significantly in 2019. In 1990 and 2019, the disease burden indicator of male pancreatic cancer was higher than that of females, and pancreatic cancer became more common as age increased, especially above 50 years old. What are the implications for public health practices?: This study mainly provided scientific data and references for the prevention and control of pancreatic cancer in people aged 50 and above.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.